Regression to normoglycaemia by fenofibrate in pre-diabetic subjects complicated with hypertriglyceridaemia: A prospective randomized controlled trial

Diabetic Medicine

Volumn 27, Issue 11, 2010, Pages 1312-1317

  Wan, Q ^a   Wang, F ^a,a   Guan, Q ^a   Liu, Y ^a   Wang, C ^b   Feng, L ^c   Gao, G ^c   Gao, L ^a   Zhao, J ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c LINYI PEOPLE'S HOSPITAL   (China)

Author keywords

Diet control; Fenofibrate; Hypertriglyceridaemia; Metformin; Pre diabetes

Indexed keywords

FENOFIBRATE; METFORMIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DRUG MECHANISM; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HUMAN; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; LIPID METABOLISM; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; FEMALE; FENOFIBRATE; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PREDIABETIC STATE; YOUNG ADULT;

EID: 77958546651     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2010.03107.x     Document Type: Article

References (11)

1. Gerstein HC, Santaguida P, Raina P, Morrison KM, Balion C, Hunt D et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007; 78: 305-312.
2. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med 2007; 24: 137-144.
3. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P et al.; Finnish Diabetes Prevention Study Group Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
4. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al.; Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
5. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002; 51: 7-18.
6. Sun Y, Zhang L, Gu HF, Han W, Ren M, Wang F et al. Peroxisome proliferator-activated receptor-α regulates the expression of pancreatic/duodenal homeobox-1 in rat insulinoma (INS-1) cells and ameliorates glucose-induced insulin secretion impaired by palmitate. Endocrinology 2008; 149: 662-671.
7. Wysocki J, Belowski D, Kalina M, Kochanski L, Okopien B, Kalina Z. Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. Int J Clin Pharmacol Ther 2004; 42: 212-217.
8. Nadeau KJ, Ehlers LB, Aguirre LE, Reusch JE, Draznin B. Discordance between intramuscular triglyceride and insulin sensitivity in skeletal muscle of Zucker diabetic rats after treatment with fenofibrate and rosiglitazone. Diabetes Obes Metab 2007; 9: 714-723.
9. Kobayashi M, Shigeta Y, Hirata Y, Omori Y, Sakamoto N, Nambu S et al. Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study. Diabetes Care 1988; 11: 495-499.
10. Wu H, Wei L, Bao Y, Lu J, Huang P, Liu Y et al. Fenofibrate reduces serum retinol-binding protein-4 by suppressing its expression in adipose tissue. Am J Physiol Endocrinol Metab 2009; 296: E628-E634.
11. Abbasi F, Chen YD, Farin HM, Lamendola C, Reaven GM. Comparison of three treatment approaches to decreasing cardiovascular disease risk in nondiabetic insulin-resistant dyslipidemic subjects. Am J Cardiol 2008; 102: 64-69.